Scarica l'app Stockscreener
5.31
0.95%
0.05
Precedente Chiudi:
$5.26
Aprire:
$5.31
Volume 24 ore:
3.80M
Relative Volume:
0.94
Capitalizzazione di mercato:
$1.45B
Reddito:
$8.10M
Utile/perdita netta:
$-92.72M
Rapporto P/E:
-14.87
EPS:
-0.3571
Flusso di cassa netto:
$-82.52M
1 W Prestazione:
-3.45%
1M Prestazione:
+5.15%
6M Prestazione:
+126.92%
1 anno Prestazione:
+182.45%
Intervallo 1D:
$5.215
$5.69
Intervallo di 1 settimana:
$4.80
$5.69
Portata 52W:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Confronta TSHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.31 | 1.44B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Chardan Capital Maintains Buy Rating on TSHA at $12 | TSHA Stock News - GuruFocus
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha doses first patient in pivotal Rett syndrome gene therapy trial - Investing.com Australia
Taysha Gene Therapies (TSHA) Advances in Rett Syndrome Gene Ther - GuruFocus
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - The Manila Times
New gene therapy trial progresses for children and adults with Rett syndrome - Stock Titan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Highlights: Can Taysha Gene Therapies Inc stock rebound after recent weaknessIPO Watch & Precise Buy Zone Tips - moha.gov.vn
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.8%What's Next? - MarketBeat
Rice Hall James & Associates LLC Buys New Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap UpHere's Why - MarketBeat
Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com - Investing.com Nigeria
Taysha Gene Therapies stock hits 52-week high at $5.98 - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Does Taysha Gene Therapies Still Offer Value After a 196.8% Year to Date Surge? - Yahoo Finance
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? - Yahoo Finance
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades - Yahoo Finance
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program - Insider Monkey
Is Taysha Gene Therapies Inc. stock recession proofQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
How analysts rate Taysha Gene Therapies Inc. stock todayBull Run & Weekly Stock Breakout Alerts - Улправда
Earnings Report: Is Taysha Gene Therapies Inc. stock recession proofWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
Breakouts Watch: Is Taysha Gene Therapies Inc. stock recession proof2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Can Taysha Gene Therapies Inc. stock beat analyst upgradesPortfolio Performance Summary & Growth Focused Stock Pick Reports - DonanımHaber
Can Taysha Gene Therapies Inc. stock rebound after recent weaknessQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - DonanımHaber
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 1-Year HighTime to Buy? - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
1,203,941 Shares in Taysha Gene Therapies, Inc. $TSHA Purchased by Stempoint Capital LP - MarketBeat
B Group Inc. Buys 545,000 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 5.51 USD - Investing.com
Taysha Gene Therapies stock hits 52-week high at 5.51 USD By Investing.com - Investing.com South Africa
200,000 Shares in Taysha Gene Therapies, Inc. $TSHA Bought by Affinity Asset Advisors LLC - MarketBeat
Taysha Gene Therapies Grants Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Can Taysha Gene Therapies Stock Hold Up When Markets Turn? - Trefis
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Would You Still Hold Taysha Gene Therapies Stock If It Fell 30%? - Trefis
Taysha Gene Therapies (TSHA) Upgraded to Buy by Goldman Sachs - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7%Still a Buy? - MarketBeat
Taysha Gene Therapies (TSHA) Receives Buy Rating from Goldman Sa - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 6.5% on Insider Selling - MarketBeat
How Taysha Gene Therapies Inc. stock reacts to oil prices2025 EndofYear Setup & Technical Confirmation Alerts - Newser
Sukumar Nagendran Sells 110,125 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Taysha Gene Therapies Insider Sold Shares Worth $1,695,906, According to a Recent SEC Filing - marketscreener.com
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):